01—Abstract
Summary
Summary of the 10-Q filed May 8, 2024. Cited figures are marked; the original filing is the authoritative source.
BeiGene, Ltd. reported a significant increase in total revenues to $751.7 milliona for the first quarter of 2024, up 67.9% from the prior year, driven primarily by an 82.0% surge in product revenue to $746.9 million.
This growth was predominantly fueled by strong performance in BRUKINSA, which saw a 131.1% year-over-year increase in net product revenue to $488.5 millionb, with notable expansion in the U.S. and Europe. The company continues to invest heavily in research and development, with R&D expenses increasing by 12.7% to $460.6 million, supporting its broad pipeline. Despite increased operating expenses, the company highlights improved operating leverage and progress towards sustainable profitability.
However, BeiGene reported a net loss of $251.2 millionc for the quarter, although this represents an improvement compared to the $348.4 million net loss in the same period last year. Financially, BeiGene maintains a strong liquidity position with $2.8 billion in cash, cash equivalents, and restricted cash as of March 31, 2024.
The company's total debt stands at $1.03 billiond, with a significant portion maturing within the next 12 months. While the company is actively managing its growth and pipeline development, investors should monitor its continued progress in commercializing its approved medicines and advancing its pipeline candidates, alongside its efforts to manage increasing operational costs.
02—Key points
Key Highlights
- Total revenues increased by 67.9% to $751.7 million in Q1 2024 compared to Q1 2023.
- Product revenue surged by 82.0% to $746.9 million in Q1 2024, driven by strong sales of BRUKINSA.
- BRUKINSA net product revenue grew 131.1% to $488.5 million in Q1 2024, with significant growth in the U.S. and Europe.
- Research and development expenses increased by 12.7% to $460.6 million in Q1 2024.
- Selling, general, and administrative expenses increased by 30.1% to $427.4 million in Q1 2024, reflecting investment in commercial activities.
- Net loss for the quarter was $251.2 million, an improvement from $348.4 million in the prior year's quarter.
- Cash, cash equivalents, and restricted cash stood at $2.8 billion as of March 31, 2024, indicating a healthy liquidity position.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q1 FY2024, BeOne Medicines Ltd. lost $0.33.
- Revenue$751.7M100.0%
- Cost of revenue−$124.9M16.6%
- Gross profit$626.7M83.4%
- Operating costs−$888.1M118.1%
- Operating income−$261.3M34.8%
- Interest, other & tax$10.2M1.4%
- Net income−$251.2M33.4%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 8, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $751.65M$447.80M | +67.9% |
| Gross Profit | $626.72M$366.01M | +71.2% |
| R&D Expenses | $460.64M$408.58M | +12.7% |
| SG&A Expenses | $427.43M$328.50M | +30.1% |
| Operating Expenses | $888.07M$737.27M | +20.5% |
| Operating Income | -$261.35M-$371.26M | +29.6% |
| Interest Expense | $12.40M$4.57M | +171.2% |
| Net Income | -$251.15M-$348.43M | +27.9% |
| EPS (Basic) | $-0.19$-0.26 | +26.9% |
| EPS (Diluted) | $-0.19$-0.26 | +26.9% |
| Shares Outstanding (Basic) | 1.36B1.35B | +0.1% |
| Shares Outstanding (Diluted) | 1.36B1.35B | +0.1% |
05—Questions
Frequently Asked Questions
What was BeiGene's revenue performance in the first quarter of 2024?
BeiGene reported a substantial increase in total revenues, reaching $751.7 million for the first quarter of 2024, a 67.9% increase compared to $447.8 million in the same period of 2023. This growth was primarily driven by a significant rise in product revenue, which increased by 82.0% to $746.9 million.
How did BRUKINSA perform in Q1 2024?
BRUKINSA demonstrated strong sales performance, with net product revenue growing by 131.1% to $488.5 million in the first quarter of 2024, compared to $211.4 million in the first quarter of 2023. Growth was particularly strong in the U.S. (153.3% increase) and Europe (242.8% increase).
What is BeiGene's current financial health and liquidity situation?
As of March 31, 2024, BeiGene had $2.8 billion in cash, cash equivalents, and restricted cash, indicating a strong liquidity position. The company had total debt of $1.03 billion, with approximately $827 million maturing within the next 12 months. While the company has an accumulated deficit of $8.2 billion, management expects current cash to fund operations for at least the next 12 months.
What are the key drivers for the increase in operating expenses?
Research and development expenses increased by 12.7% to $460.6 million, reflecting continued investment in pipeline expansion and clinical trials. Selling, general, and administrative expenses rose by 30.1% to $427.4 million, primarily due to investments in commercial activities to support product launches and market growth, particularly for BRUKINSA in the U.S. and Europe.
06—Continue